Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models

[V4Q5]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Garona, Juan, Pifano, Marina, Pastrian, María Belén, Gómez, Daniel Eduardo, Ripoll, Giselle Vanina, Alonso, Daniel Fernando
Formato:	Articulo
Lenguaje:	Inglés
Publicado:	2016
Materias:	Medicina Salud vasopressin analogue synthetic peptide derivative [V4Q5]dDAVP V2r agonist chemotherapy combinational therapy hormone-independent breast cancer antimetastatic
Acceso en línea:	http://sedici.unlp.edu.ar/handle/10915/105077 https://link.springer.com/article/10.1007/s10585-016-9799-5
Aporte de:	SEDICI (UNLP) de Universidad Nacional de La Plata

id	I19-R120-10915-105077
record_format	dspace
institution	Universidad Nacional de La Plata
institution_str	I-19
repository_str	R-120
collection	SEDICI (UNLP)
language	Inglés
topic	Medicina Salud vasopressin analogue synthetic peptide derivative [V4Q5]dDAVP V2r agonist chemotherapy combinational therapy hormone-independent breast cancer antimetastatic
spellingShingle	Medicina Salud vasopressin analogue synthetic peptide derivative [V4Q5]dDAVP V2r agonist chemotherapy combinational therapy hormone-independent breast cancer antimetastatic Garona, Juan Pifano, Marina Pastrian, María Belén Gómez, Daniel Eduardo Ripoll, Giselle Vanina Alonso, Daniel Fernando Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
topic_facet	Medicina Salud vasopressin analogue synthetic peptide derivative [V4Q5]dDAVP V2r agonist chemotherapy combinational therapy hormone-independent breast cancer antimetastatic
description	[V<sup>4</sup>Q<sup>5</sup>]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V<sup>4</sup>Q<sup>5</sup>]dDAVP inhibits angiogenesis and metastatic progression of the disease without overt toxicity. Despite chemotherapy remaining as a primary therapeutic option for aggressive breast cancer, its use is limited by low selectivity and associated adverse effects. In this regard, we evaluated potential combinational benefits by adding [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard-of-care chemotherapy. In vitro, combination of [V<sup>4</sup>Q<sup>5</sup>]dDAVP with sub-IC<sub>50</sub> concentrations of paclitaxel or carmustine resulted in a cooperative inhibition of breast cancer cell growth in comparison to single-agent therapy. In vivo antitumour efficacy of [V<sup>4</sup>Q<sup>5</sup>]dDAVP addition to chemotherapy was first evaluated using the triple-negative MDA-MB-231 breast cancer xenograft model. Tumour-bearing mice were treated with i.v. injections of [V<sup>4</sup>Q<sup>5</sup>]dDAVP (0.3 lg/kg, thrice weekly) in combination with weekly cycles of paclitaxel (10 mg/kg i.p.). After 6 weeks of treatment, combination regimen resulted in greater tumour growth inhibition compared to monotherapy. [V<sup>4</sup>Q<sup>5</sup>]dDAVP addition was also associated with reduction of local aggressiveness, and impairment of tumour invasion and infiltration of the skin. Benefits of combined therapy were confirmed in the hormone-independent and metastatic F3II breast cancer model by combining [V<sup>4</sup>Q<sup>5</sup>]dDAVP with carmustine (25 mg/kg i.p.). Interestingly, [V<sup>4</sup>Q<sup>5</sup>]dDAVP plus cytotoxic agents severely impaired colony forming ability of tumour cells and inhibited breast cancer metastasis to lung. The present study shows that [V<sup>4</sup>Q<sup>5</sup>]dDAVPmay complement conventional chemotherapy by modulating metastatic progression and early stages of microtumour establishment, and thus supports further preclinical testing of the compound for the management of aggressive breast cancer.
format	Articulo Articulo
author	Garona, Juan Pifano, Marina Pastrian, María Belén Gómez, Daniel Eduardo Ripoll, Giselle Vanina Alonso, Daniel Fernando
author_facet	Garona, Juan Pifano, Marina Pastrian, María Belén Gómez, Daniel Eduardo Ripoll, Giselle Vanina Alonso, Daniel Fernando
author_sort	Garona, Juan
title	Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
title_short	Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
title_full	Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
title_fullStr	Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
title_full_unstemmed	Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
title_sort	addition of vasopressin synthetic analogue [v<sup>4</sup>q<sup>5</sup>]ddavp to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
publishDate	2016
url	http://sedici.unlp.edu.ar/handle/10915/105077 https://link.springer.com/article/10.1007/s10585-016-9799-5
work_keys_str_mv	AT garonajuan additionofvasopressinsyntheticanaloguevsup4supqsup5supddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels AT pifanomarina additionofvasopressinsyntheticanaloguevsup4supqsup5supddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels AT pastrianmariabelen additionofvasopressinsyntheticanaloguevsup4supqsup5supddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels AT gomezdanieleduardo additionofvasopressinsyntheticanaloguevsup4supqsup5supddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels AT ripollgisellevanina additionofvasopressinsyntheticanaloguevsup4supqsup5supddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels AT alonsodanielfernando additionofvasopressinsyntheticanaloguevsup4supqsup5supddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels
bdutipo_str	Repositorios
_version_	1764820442825097219

Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models

Ejemplares similares